Kenvue Inc. (NYSE:KVUE) Shares Purchased by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. boosted its holdings in Kenvue Inc. (NYSE:KVUE) by 5.5% during the fourth quarter, HoldingsChannel reports. The fund owned 446,047 shares of the company’s stock after buying an additional 23,381 shares during the period. PNC Financial Services Group Inc.’s holdings in Kenvue were worth $9,523,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in KVUE. CWA Asset Management Group LLC acquired a new position in Kenvue in the third quarter valued at approximately $307,000. Assetmark Inc. lifted its holdings in Kenvue by 29.9% in the third quarter. Assetmark Inc. now owns 67,796 shares of the company’s stock valued at $1,568,000 after acquiring an additional 15,593 shares during the last quarter. Atria Investments Inc lifted its holdings in Kenvue by 13.8% in the third quarter. Atria Investments Inc now owns 111,326 shares of the company’s stock valued at $2,575,000 after acquiring an additional 13,500 shares during the last quarter. Crossmark Global Holdings Inc. lifted its holdings in Kenvue by 8.1% in the third quarter. Crossmark Global Holdings Inc. now owns 57,262 shares of the company’s stock valued at $1,324,000 after acquiring an additional 4,298 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in Kenvue in the third quarter valued at approximately $213,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on KVUE shares. UBS Group decreased their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Canaccord Genuity Group upped their price target on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Piper Sandler upped their price target on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday, February 24th. Finally, Citigroup decreased their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $23.75.

Kenvue Stock Down 1.7 %

Kenvue stock opened at $23.50 on Wednesday. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The stock’s fifty day simple moving average is $21.74 and its 200-day simple moving average is $22.36. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $44.92 billion, a P/E ratio of 44.35, a P/E/G ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.49%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.